BioSpace News Archive

Cybin Inc. today announced that the first participants have been dosed with CYB004 in its ongoing three-part Phase 1 clinical trial evaluating intravenous N,N-dimethyltryptamine (“IV DMT”) and CYB004 in healthy volunteers.

Oculis Holding AG announces that its Head of Development, Dr. Bastian Dehmel, will be participating in the 2023 EuDES (European Dry Eye Society) Meeting in Munich, Germany on June 2-3, 2023.

NeuBase Therapeutics, Inc. announced that the Company’s management will participate in the Jefferies Healthcare Conference being held at the Marriott Marquis in New York, NY on June 7-9, 2023.

Innovative Cellular Therapeutics, Inc. (ICT) today announced the Company presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual meeting in Los Angeles, California. May 16-20, 2023.

Rani Therapeutics Holdings, Inc. today announced that it has appointed Kate McKinley as its Chief Business Officer.

Ikena Oncology, Inc. today announced that management will participate in TD Cowen’s 4th Annual Oncology Innovation Summit taking place May 30-31, 2023, and the Jefferies Healthcare Conference taking place June 7-9, 2023.

Lisata Therapeutics, Inc. today announced protocol changes to the ongoing ASCEND trial, a Phase 2b trial evaluating LSTA1, Lisata’s lead investigational drug, in combination with standard-of-care (“SOC”) gemcitabine/nab-paclitaxel in patients with first-line, metastatic pancreatic ductal adenocarcinoma (“mPDAC”).

BIOREM Inc. today announced results for the three month period ended March 31, 2023.

Highlighting new biomarker data and research supporting precision development of the “‘stinel” class at the 2023 ASCP Annual Meeting.

With the launch of a new website dedicated to their global clinical trials, Paradigm Biopharmaceuticals Ltd. aims to provide relief to millions of osteoarthritis sufferers worldwide by developing a new injectable drug.